drugset / Trial / NCT00025181
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
Phase 1
Completed
19 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining monoclonal antibody therapy and vaccine therapy in treating patients who have stage III or stage IV melanoma that has been removed during surgery.
Timeline
- Start
- 2001-10
- Primary completion
- 2003-01
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Background | MART-1 antigen | Vaccine | — | Subcutaneous |
| Background | gp100 antigen | Peptide | — | — |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | — |
| Background | tyrosinase peptide | Peptide | — | — |